Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Amryt Pharma to Hold

Maxim Group Downgrades Amryt Pharma to Hold

Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.

byBenzinga Newsdesk

January 10, 2023

1 minute read

Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.

Analyst Ratings

What To Know About Morgan Stanley’s Upgrade of Starbucks

By Benzinga Insights

January 16, 1:00 PM

Morgan Stanley upgraded its rating of Starbucks (NASDAQ:SBUX) to Overweight with a price target of $120.00, changing its…

SBUX

GeoVax Expands Rights Under NIH COVID-19 License To Include Mpox And Smallpox; Financial Terms Of The License Agreement Were Not Disclosed

By Benzinga Newsdesk

December 19, 10:05 AM

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological

GOVX

News

International Monetary Fund Chief Economist Gourinchas Says Central Banks’ Fight Against Inflation Will Last Well Into 2024; Inflation Will Not Be Returned To Target In 2023, But Will Be Closer To Target In 2024

By Benzinga Newsdesk

October 11, 4:37 PM

- Reuters

SPY

Piper Sandler Maintains Overweight on Veeva Sys, Lowers Price Target to $204

By Benzinga Newsdesk

January 9, 7:54 AM

Piper Sandler analyst Brent Bracelin maintains Veeva Sys (NYSE:VEEV) with a Overweight and lowers the price target from $220 to $204.

VEEV

Maxim Group Downgrades Amryt Pharma to Hold

Related Posts

What To Know About Morgan Stanley’s Upgrade of Starbucks

GeoVax Expands Rights Under NIH COVID-19 License To Include Mpox And Smallpox; Financial Terms Of The License Agreement Were Not Disclosed

International Monetary Fund Chief Economist Gourinchas Says Central Banks’ Fight Against Inflation Will Last Well Into 2024; Inflation Will Not Be Returned To Target In 2023, But Will Be Closer To Target In 2024

Piper Sandler Maintains Overweight on Veeva Sys, Lowers Price Target to $204